Dermatologic Therapy最新文献

筛选
英文 中文
Identifying an Early Improvement Cutoff in Psoriasis Area and Severity Index for Outcome Prediction Across Systemic Treatments 确定银屑病区域的早期改善截止点和系统性治疗结果预测的严重程度指数
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-11-06 DOI: 10.1155/dth/6867179
Siqi Li, Yuxiong Jiang, Min Dai, Qianyu Chen, Dawei Huang, Yu Wang, Yifan Hu, Yuanwenke Zhang, Suyang Lin, Xilin Zhang, Qian Yu, Yuling Shi
{"title":"Identifying an Early Improvement Cutoff in Psoriasis Area and Severity Index for Outcome Prediction Across Systemic Treatments","authors":"Siqi Li, Yuxiong Jiang, Min Dai, Qianyu Chen, Dawei Huang, Yu Wang, Yifan Hu, Yuanwenke Zhang, Suyang Lin, Xilin Zhang, Qian Yu, Yuling Shi","doi":"10.1155/dth/6867179","DOIUrl":"https://doi.org/10.1155/dth/6867179","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Early identification of treatment response is clinically important in psoriasis management, as it may facilitate timely treatment modification and reduce exposure to ineffective therapies. Although early improvement in the Psoriasis Area and Severity Index (PASI) has been associated with long-term outcomes for individual therapies, a broadly applicable early PASI threshold across different treatment modalities in real-world practice remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate the predictive value of early PASI improvement for subsequent PASI90 achievement across multiple psoriasis treatment modalities and to identify a clinically meaningful early PASI response threshold.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective, multicenter real-world cohort study (approval no. 2020-36) included adult patients with moderate-to-severe plaque psoriasis receiving methotrexate, phototherapy, interleukin (IL)-17 inhibitors, or IL-23 inhibitors. Receiver operating characteristic (ROC) curve analyses were used to evaluate the predictive performance of week-4 PASI improvement for achieving PASI90 at 3 and 6 months. The optimal early response threshold was identified using the Youden Index. Multivariable logistic regression analyses were conducted to assess the independent association between early PASI response and subsequent PASI90 achievement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 2023 patients were included in the analysis. The optimal week-4 PASI improvement threshold for predicting PASI90 at 3 months was 62% for IL-17 inhibitors, 62% for IL-23 inhibitors, 59% for methotrexate, and 61% for phototherapy. Multivariable logistic regression analyses further demonstrated that a PASI improvement of approximately 60% at Week 4 was independently associated with a higher likelihood of achieving PASI90 at 3 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Achieving PASI60 at Week 4 serves as a consistent early indicator of subsequent PASI90 response across multiple psoriasis treatment modalities. These findings suggest that PASI60 may represent a potentially generalizable early-response threshold; however, external validation in independent populations is required before its incorporation into routine clinical decision-making.</p>\u0000 \u0000 <p><b>Trial Registration:</b> Chinese Clinical Trial Registry: ChiCTR2000036186</p>\u0000 </section>\u0000","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6867179","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149356352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tildrakizumab in the Treatment of Palmoplantar Plaque Psoriasis—A Multicenter Real-World Retrospective Study Tildrakizumab治疗掌跖斑块银屑病-多中心真实世界回顾性研究
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-11-05 DOI: 10.1155/dth/9180273
Bárbara Vieira Granja, Júlia Vide, Nuno Preto Gomes, Tiago Torres, Pedro Mendes Bastos, Paulo Morais, Sofia Magina
{"title":"Tildrakizumab in the Treatment of Palmoplantar Plaque Psoriasis—A Multicenter Real-World Retrospective Study","authors":"Bárbara Vieira Granja,&nbsp;Júlia Vide,&nbsp;Nuno Preto Gomes,&nbsp;Tiago Torres,&nbsp;Pedro Mendes Bastos,&nbsp;Paulo Morais,&nbsp;Sofia Magina","doi":"10.1155/dth/9180273","DOIUrl":"https://doi.org/10.1155/dth/9180273","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The palmoplantar region is a high-impact area in psoriasis, with a particularly negative impact on patients’ quality of life. Tildrakizumab has shown efficacy, effectiveness, and safety in the treatment of moderate-to-severe plaque psoriasis but has limited evidence in high-impact areas. The aim of this study was to retrospectively investigate the effectiveness of tildrakizumab in palmoplantar psoriasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a multicentric, real-world, retrospective study of patients with generalized psoriasis with palmoplantar involvement treated with tildrakizumab 100 mg. Patient data were collected from clinical records, and psoriasis severity was evaluated using the ppPASI, ppPASI &lt; 3, and ppPASI &lt; 1 as co-primary endpoints and the PASI, PGA, BSA, and DLQI as secondary endpoints at baseline and at Weeks 28, 40, and 52 of treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eighteen patients were included. Mean PASI, BSA, and PGA scores showed a marked reduction from baseline (9.7 ± 6.2; 11.0 ± 7.0; 3.3 ± 0.7) to Week 28 (1.5 ± 1.3; 1.5 ± 1.5; 1.4 ± 1.1), with further improvement at Week 40 (0.9 ± 1.0; 0.9 ± 1.0; 0.9 ± 0.7) and stabilization at Week 52 (1.1 ± 2.2; 1.0 ± 1.6; 0.9 ± 1.1). DLQI scores also improved substantially from baseline (15.1 ± 3.9) to Week 28 (3.7 ± 5.4) and Week 40 (1.4 ± 2.4), with a slight increase between Week 40 and Week 52 (2.3 ± 4.3). Mean ppPASI improved from 15.4 ± 11.1 at baseline to 4.8 ± 12.0 at Week 28 and 1.2 ± 1.6 at Week 40, stabilizing at Week 52 (1.5 ± 2.7). The proportion of patients achieving absolute ppPASI &lt; 3 and ppPASI &lt; 1 increased consistently over time, reaching 61%, 77%, and 81% for ppPASI &lt; 3 and 44%, 62%, and 75% for ppPASI &lt; 1 at Weeks 28, 40, and 52, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study, one of the few with 52-week real-world data specifically in palmoplantar psoriasis, confirms that tildrakizumab is a valuable therapeutic option for the treatment of psoriasis in this location, providing effective disease control.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9180273","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149356402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improved Quality of Life and Sleep in Psoriasis Patients Treated With Guselkumab: The CASSIOPEE Study Guselkumab治疗改善银屑病患者的生活质量和睡眠质量:CASSIOPEE研究
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-11-05 DOI: 10.1155/dth/9751619
L. Misery, Cristina Bulai Livideanu, A. C. Fougerousse, D. Staumont-Sallé, J. Baraut, S. Chaalal, R. Parker, M. A. Richard
{"title":"Improved Quality of Life and Sleep in Psoriasis Patients Treated With Guselkumab: The CASSIOPEE Study","authors":"L. Misery,&nbsp;Cristina Bulai Livideanu,&nbsp;A. C. Fougerousse,&nbsp;D. Staumont-Sallé,&nbsp;J. Baraut,&nbsp;S. Chaalal,&nbsp;R. Parker,&nbsp;M. A. Richard","doi":"10.1155/dth/9751619","DOIUrl":"https://doi.org/10.1155/dth/9751619","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Psoriasis has physical, psychological, and social consequences that extend beyond visible lesions. Quality of life (QoL) is frequently affected by fatigue, sleep disturbance, and impaired intimacy or social functioning. Although biologics can achieve durable skin clearance, their broader effects on daily well-being in routine practice are less well documented. The CASSIOPEE study assessed these multidimensional outcomes in patients treated with guselkumab.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate the impact of guselkumab on QoL and objectively measured sleep in adults with moderate-to-severe psoriasis treated in routine clinical practice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>CASSIOPEE was a prospective, noninterventional, multicentre French study. Adults with moderate-to-severe psoriasis initiating guselkumab were followed for 6 months. The primary endpoint was Dermatology Life Quality Index (DLQI) response at month 6 (M6). Secondary outcomes included patient-reported measures of general health (EQ-5D-5L), fatigue (FACIT-Fatigue), anhedonia (SHAPS), sexual QoL (RSS), cognitive function (PDQ-5), alexithymia (TAS-20), and monthly electronic ratings of pain and pruritus. Sleep and physical activity were continuously monitored using a wearable device.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 207 enrolled patients, 88.9% achieved the DLQI minimal clinically important difference (MCID) by M6 and 60.1% had a DLQI score of 0/1. Sleep duration and quality improved, with 74.5% of patients gaining &gt; 15 min/night and the proportion with high sleep quality increasing from 4.2% to 23.8%. Patient-reported outcomes showed marked reductions in pruritus, skin pain, and fatigue, together with improvements in general health, sexual QoL, cognitive function, and anhedonia. Clinical effectiveness was reflected by 88.1% of patients achieving a Physician’s Global Assessment (PGA) score ≤ 1 and 55.1% reaching complete skin clearance at M6. Guselkumab was well tolerated; most adverse events were mild and 1.8% led to treatment discontinuation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In routine practice, guselkumab was associated with broad benefits across skin and QoL domains, including a marked improvement in wearable-confirmed sleep outcomes that paraleled symptom relief.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9751619","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149356403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early Intervention With Low-Fluence Q-Switched 1064-nm Nd:YAG Laser is Associated With Improved Clinical Outcomes in Postinflammatory Hyperpigmentation: A Retrospective Cohort Study 早期干预低通量q开关1064 nm Nd:YAG激光与改善炎症后色素沉着的临床结果相关:一项回顾性队列研究
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-11-05 DOI: 10.1155/dth/6788087
Huan Luo, Zhiyong Li, Xuanqi Feng, Jingyu Zhang, Xiao Luo, Hongxiang Chen
{"title":"Early Intervention With Low-Fluence Q-Switched 1064-nm Nd:YAG Laser is Associated With Improved Clinical Outcomes in Postinflammatory Hyperpigmentation: A Retrospective Cohort Study","authors":"Huan Luo,&nbsp;Zhiyong Li,&nbsp;Xuanqi Feng,&nbsp;Jingyu Zhang,&nbsp;Xiao Luo,&nbsp;Hongxiang Chen","doi":"10.1155/dth/6788087","DOIUrl":"https://doi.org/10.1155/dth/6788087","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>Traditional postinflammatory hyperpigmentation (PIH) management delays laser intervention until lesion stabilization, potentially forfeiting a critical therapeutic window. This study aimed to evaluate the efficacy and safety of early active (EA) phase initiation of low-fluence Q-switched 1064-nm Nd:YAG laser treatment (4–8 weeks postonset) versus the relatively stable (RS) phase (&gt; 8 weeks postonset).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>In this single-center retrospective cohort, 48 PIH patients were stratified by disease duration: 4–8 weeks postonset for the EA-phase group (<i>n</i> = 28) and &gt; 8 weeks postonset for the RS-phase group (<i>n</i> = 20). All patients received three low-fluence (1.8–3.0 J/cm<sup>2</sup>) Q-switched 1064-nm sessions at 4-week intervals. The primary endpoint was objective lesion diameter reduction at 3 months posttreatment, quantified via a multispectral imaging device. Secondary endpoints included the modified Post-Acne Hyperpigmentation Index (mPAHPI), Physician Global Assessment (PGA), patient satisfaction scores, and safety.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Early intervention was associated with significantly greater objective lesion diameter reduction rate (median 54.46% vs. 13.13%; <i>p</i> &lt; 0.001), greater mPAHPI improvement rate (41.39% vs. 12.13%; <i>p</i> = 0.003), and greater PGA improvement rate (60.00% vs. 25.00%; <i>p</i> = 0.001). Primary multivariable linear regression identified early intervention as an independent predictor for greater objective diameter reduction (unstandardized <i>B</i> = 39.60; <i>p</i> &lt; 0.001), mPAHPI improvement (<i>B</i> = 23.68; <i>p</i> = 0.001), and PGA improvement (<i>B</i> = 27.14; <i>p</i> = 0.001). Supporting logistic regression consistently indicated early intervention as an independent predictor of dichotomized clinical success (adjusted odds ratios: 4.815–14.108; all <i>p</i>s &lt; 0.05). Early treatment was associated with significant resolution of baseline erythema (82.1% improvement; <i>p</i> = 0.016). Mild hypopigmentation occurred exclusively in the RS-phase group (25.0%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Initiating low-fluence Q-switched 1064-nm laser therapy at 4–8 weeks after PIH onset is associated with enhanced pigment clearance and inflammation resolution compared with delayed intervention, suggesting the potential utility of a stage-specific paradigm for PIH management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6788087","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149356054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanisms and Therapeutic Advances in Antihistamine-Refractory Chronic Spontaneous Urticaria 抗组胺难治性慢性自发性荨麻疹的机制及治疗进展
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-11-04 DOI: 10.1155/dth/5986850
Xiaoran Tao, Xiaoli Yang, Xinyu Huang, Chen Xu, Panling Wei, Min Fan, Zaixing Wang
{"title":"Mechanisms and Therapeutic Advances in Antihistamine-Refractory Chronic Spontaneous Urticaria","authors":"Xiaoran Tao,&nbsp;Xiaoli Yang,&nbsp;Xinyu Huang,&nbsp;Chen Xu,&nbsp;Panling Wei,&nbsp;Min Fan,&nbsp;Zaixing Wang","doi":"10.1155/dth/5986850","DOIUrl":"https://doi.org/10.1155/dth/5986850","url":null,"abstract":"<p>Chronic spontaneous urticaria (CSU) is a common autoimmune skin disorder characterized by recurrent wheals and/or angioedema lasting more than 6 weeks. A substantial proportion of patients remain symptomatic despite treatment with standard or high-dose H1-antihistamines, defined as antihistamine-refractory CSU. This condition is associated with significant disease burden, reduced quality of life, and limited therapeutic options. The pathogenesis of refractory CSU is complex and heterogeneous, involving aberrant mast cell activation through IgE-dependent and IgE-independent pathways, dysregulated cytokine networks, and contributions from basophils, eosinophils, and T cells. Such immune imbalance underlies variable responses to conventional therapies. Current management primarily relies on omalizumab and cyclosporine, but their efficacy is limited in a subset of patients. Advances in understanding the disease mechanisms have led to the development of novel therapeutic strategies, including biologics targeting interleukins (IL-4, IL-5, IL-17, and TSLP), Bruton’s tyrosine kinase inhibitors, anti-KIT antibodies, MRGPRX2 antagonists, and Janus kinase inhibitors. These emerging agents show promising efficacy in clinical trials and may help refine individualized treatment approaches. Further large-scale studies are warranted to validate their safety and effectiveness, ultimately improving outcomes for patients with refractory CSU.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5986850","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149355822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug Survival of Biologic Therapy for Moderate-to-Severe Psoriasis in a Latin American Specialized Psoriasis Center: A 7-Year Experience 拉丁美洲专业银屑病中心中重度银屑病生物治疗的药物生存期:7年经验
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-11-03 DOI: 10.1155/dth/1864210
Laura I. Vallejo-Londoño, Sneider Torres-Soto, Valentina Naranjo-Tobón, Sebastián Bedoya-Mejía, Juliana Madrigal-Cadavid, Susana Chiquito-García, Ángela Londoño-García
{"title":"Drug Survival of Biologic Therapy for Moderate-to-Severe Psoriasis in a Latin American Specialized Psoriasis Center: A 7-Year Experience","authors":"Laura I. Vallejo-Londoño,&nbsp;Sneider Torres-Soto,&nbsp;Valentina Naranjo-Tobón,&nbsp;Sebastián Bedoya-Mejía,&nbsp;Juliana Madrigal-Cadavid,&nbsp;Susana Chiquito-García,&nbsp;Ángela Londoño-García","doi":"10.1155/dth/1864210","DOIUrl":"https://doi.org/10.1155/dth/1864210","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Drug survival integrates effectiveness, safety, and access in routine psoriasis care, yet real-world Latin American data are scarce. We assessed drug survival and explanatory factors of discontinuation among bio-naïve adults with moderate-to-severe psoriasis in Colombia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective cohort study using secondary electronic health record data from a multidisciplinary clinic in Medellín, Colombia (CLIPSO) from January 2018 to December 2024. Eligible adults met at least one severity criterion (PASI ≥ 10, BSA ≥ 10, or DLQI ≥ 10), initiated a first biologic, and had ≥ 3 months of treatment. Drug survival was the time from initiation to discontinuation for any reason. Records with &gt; 60% missing data underwent targeted chart review to verify key variables. Kaplan–Meier curves (log-rank) and Cox proportional hazards models were used.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The cohort included 1098 patients (48.8% women); 30.1% discontinued therapy. Therapeutic failure was the leading reason (58.2%), whereas adverse events were less frequently reported (11.2%). Drug survival declined to ∼50% at 60 months and ∼43% by 80 months. In multivariable analyses, adalimumab showed higher discontinuation risk (aHR = 1.36; 95% CI: 1.0001–1.84), whereas risankizumab (aHR = 0.41; 95% CI: 0.21–0.80), guselkumab (aHR = 0.42; 95% CI: 0.26–0.68), ixekizumab (aHR = 0.59; 95% CI: 0.41–0.85), and secukinumab (aHR = 0.67; 95% CI 0.47–0.97) showed better persistence. The presence of a high burden of comorbidities increased risk (aHR = 1.71; 95% CI: 1.12–2.63), whereas prior systemic therapy was protective (aHR = 0.45; 95% CI: 0.28–0.72).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Drug survival differed across biologics in this Colombian real-world cohort, with interleukin-23 and interleukin-17 inhibitors demonstrating greater persistence in both bivariate and multivariable models and comorbidity burden identifying patients at higher risk of discontinuation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1864210","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149355989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Diagnostics to Survival Prediction: A Systematic Review of Artificial Intelligence Applications in Merkel Cell Carcinoma 从诊断到生存预测:人工智能在默克尔细胞癌中的应用的系统综述
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-11-01 DOI: 10.1155/dth/1099619
Jonathan Mokhtar, Noora Jatan, Éli Blais, Victoria Zecchin Ferrara, Moshe Assouline, Olivier Mathieu, Alexandre G. Lellouch
{"title":"From Diagnostics to Survival Prediction: A Systematic Review of Artificial Intelligence Applications in Merkel Cell Carcinoma","authors":"Jonathan Mokhtar,&nbsp;Noora Jatan,&nbsp;Éli Blais,&nbsp;Victoria Zecchin Ferrara,&nbsp;Moshe Assouline,&nbsp;Olivier Mathieu,&nbsp;Alexandre G. Lellouch","doi":"10.1155/dth/1099619","DOIUrl":"https://doi.org/10.1155/dth/1099619","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer with substantial mortality and limited prognostic granularity under current staging systems. Artificial intelligence (AI) has shown promise across oncology, but no synthesis has yet evaluated its application specifically to MCC across the clinical continuum, from detection to survival prediction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This systematic review followed PRISMA and Cochrane guidelines and was prospectively registered with PROSPERO. Four databases (PubMed, Embase, Scopus, and CENTRAL) were searched from inception through June 18, 2026. Eligible studies evaluated AI, machine learning, or computational models using human MCC data. Given anticipated heterogeneity in predictive targets and metrics, a narrative synthesis was performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 950 records identified, seven studies published between 2021 and 2026 met inclusion criteria. Four addressed prognosis or survival, two addressed diagnosis or early detection, and one addressed treatment-receipt prediction. The best-performing survival model achieved an AUROC of 0.89 (internal) and 0.81 (external validation), with a concordance index of 0.93. Other analyses suggested improved model fit or additional prognostic information beyond conventional AJCC staging, although direct comparisons of discrimination were not consistently available. A smartphone-based diagnostic tool achieved an AUC of 0.80 for general malignant-lesion triage, although sensitivity fell from 82.5% to 67.6% under a real-world, STARD-compliant worst-case analysis; importantly, the cohort included only one MCC lesion, which both the CNN and teledermatology assessment classified as low risk, precluding meaningful MCC-specific performance estimation. A blood-based repertoire-sequencing model reported near-perfect discrimination but lacked independent MCC validation. Overall risk of bias was high, with the “analysis” domain most frequently downgraded; no study integrating multimodal data was identified.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>AI applications in MCC remain early stage but demonstrate meaningful potential to refine prognostic stratification beyond conventional staging, although MCC-specific diagnostic evidence remains severely limited. Broader external validation and multimodal data integration represent the field’s most pressing needs before clinical translation is warranted.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1099619","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149355753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical, Systemic Inflammatory, and Metabolic Responses to Anti-IL-17 and Anti-IL-23 Monoclonal Antibodies in Psoriasis: A Comparative Real-World Study 银屑病患者抗il -17和抗il -23单克隆抗体的临床、全身炎症和代谢反应:一项比较现实世界的研究
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-11-01 DOI: 10.1155/dth/9317797
Berna Solak, Mizgin Gülmez, Sabiyya Özgün, Nilüfer Ertem Günegül, Kemal Nas
{"title":"Clinical, Systemic Inflammatory, and Metabolic Responses to Anti-IL-17 and Anti-IL-23 Monoclonal Antibodies in Psoriasis: A Comparative Real-World Study","authors":"Berna Solak,&nbsp;Mizgin Gülmez,&nbsp;Sabiyya Özgün,&nbsp;Nilüfer Ertem Günegül,&nbsp;Kemal Nas","doi":"10.1155/dth/9317797","DOIUrl":"https://doi.org/10.1155/dth/9317797","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Clinical scoring systems like PASI are gold standards for evaluating psoriasis treatment, yet they may not fully capture systemic biological responses. We aimed to compare the longitudinal effects of anti-IL-17 and anti-IL-23 monoclonal antibodies on systemic inflammatory markers and lipid profiles.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective cohort study included 237 patients with moderate-to-severe plaque psoriasis treated with anti-IL-17 (<i>n</i> = 157) or anti-IL-23 (<i>n</i> = 80) monoclonal antibodies. Clinical severity (PASI, DLQI, and DAPSA), systemic inflammatory indices (NLR, MLR, IBI, and MHR), HDL cholesterol, LDL cholesterol, and triglycerides were evaluated at baseline, Week 4, and Week 16.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Both groups achieved comparable and significant clinical improvements at Week 16, with no significant differences in PASI 75/90 response rates (<i>p</i> &gt; 0.05). However, clinical score reductions did not correlate with changes in inflammatory markers (<i>p</i> &gt; 0.05). Anti-IL-17 group demonstrated a more rapid systemic response, significantly reducing NLR by Week 4 (<i>p</i> &lt; 0.001), a change significantly more pronounced than in the anti-IL-23 group (<i>p</i> = 0.041). By Week 16, NLR decreased significantly in both groups, whereas within-group reductions in MLR and IBI reached significance only in the anti-IL-17 group; however, the between-group differences in these changes were not statistically significant. Conversely, a small but significant reduction in HDL cholesterol was observed exclusively in the anti-IL-23 group by Week 16 (median within-patient change 2.0 mg/dL [IQR −1.0 to 6.0]; <i>p</i> = 0.002), resulting in a significant inter-class difference (<i>p</i> = 0.021).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our comparative analysis suggests that while anti-IL-17 and anti-IL-23 monoclonal antibodies offer similar clinical efficacy, they may differ in their systemic inflammatory and metabolic effects. Anti-IL-17 biologics were associated with an earlier reduction in NLR. Conversely, the significant reduction in HDL levels observed with anti-IL-23 biologics is of small magnitude and uncertain clinical significance, but may warrant metabolic monitoring until confirmed in larger, longer cohorts. The lack of correlation between skin clearance and biological stabilization suggests that clinical scores alone may be insufficient to monitor the total systemic burden in psoriasis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9317797","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149355754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bimekizumab Reinitiation Following Treatment Interruption Between Two Open-Label Extension Periods: A North American Study in Participants With Moderate to Severe Plaque Psoriasis 在两个开放标签延长期之间治疗中断后再启动比美珠单抗:一项北美研究,参与者为中度至重度斑块性银屑病
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-10-28 DOI: 10.1155/dth/7634377
Phoebe Rich, Seth Forman, Benjamin Ehst, Melinda Gooderham, José Manuel López Pinto, Markus Kaspar, Sarah Kavanagh, Kim A. Papp
{"title":"Bimekizumab Reinitiation Following Treatment Interruption Between Two Open-Label Extension Periods: A North American Study in Participants With Moderate to Severe Plaque Psoriasis","authors":"Phoebe Rich,&nbsp;Seth Forman,&nbsp;Benjamin Ehst,&nbsp;Melinda Gooderham,&nbsp;José Manuel López Pinto,&nbsp;Markus Kaspar,&nbsp;Sarah Kavanagh,&nbsp;Kim A. Papp","doi":"10.1155/dth/7634377","DOIUrl":"https://doi.org/10.1155/dth/7634377","url":null,"abstract":"<p>People with moderate to severe plaque psoriasis receiving long-term biologic treatment may experience interruptions. It is important to assess response maintenance during interruptions and response recapture upon reinitiation. The BE RADIANT open-label extension (OLE) and BE BRIGHT OLE studies investigated bimekizumab efficacy and safety up to 3 and 4 years, respectively (including feeder studies). Some US/Canadian participants completing the OLEs (with any feeder study treatment) experienced bimekizumab treatment interruption before entering a second OLE (OLE2; 48 weeks). We report efficacy and safety upon bimekizumab reinitiation following this real-world interruption. Analyzed participants received bimekizumab every 8 weeks (Q8W) for at least the final 80 weeks of the first OLE. After interruption, those with Investigator’s Global Assessment (IGA) ≤ 2 at OLE2 baseline received bimekizumab Q8W; those with IGA ≥ 3 received bimekizumab Q4W to Week 16, and then Q8W. Psoriasis Area and Severity Index (PASI), IGA, and Dermatology Life Quality Index (DLQI) scores/categories were assessed at the last preinterruption timepoint and throughout OLE2 (observed cases). Treatment-emergent adverse events (TEAEs) are reported using exposure-adjusted incidence rates per 100 participant-years (PY). In total, 217 participants entered OLE2 following bimekizumab treatment interruption (median duration [range]: 5 [1–12] months). PASI = 0 was achieved by 72.0% before interruption and maintained by 19.2% at OLE2 baseline; PASI = 0 was recaptured by OLE2 Week 12 (68.4%) and sustained to OLE2 Week 48 (68.2%). IGA and DLQI responses followed similar trends. The TEAE rate during OLE2 was 84.2/100 PY (serious TEAEs: 6.0/100 PY; discontinuations due to TEAEs: 2.1/100 PY). Overall, responses were well-maintained during treatment interruption; clinical efficacy responses were largely recaptured after 3 months of bimekizumab retreatment and maintained through 1 year with no unexpected safety findings. These results suggest that bimekizumab is suitable for people with moderate to severe plaque psoriasis undergoing treatment interruptions, in addition to those being treated continuously.</p><p><b>Trial Registration:</b> ClinicalTrials.gov identifier (NCT03598790) and (NCT03536884).</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7634377","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149356850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Efficacy of IL-17A Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis IL-17A抑制剂治疗中重度斑块性银屑病的比较疗效:网络荟萃分析
IF 1 4区 医学
Dermatologic Therapy Pub Date : 2026-10-25 DOI: 10.1155/dth/9319875
Quan Zhou, Jingyue Ma, Xinzu Tong, Zhimin Wang, Huiping Wang, Powei Wu, Wangyang Zhao, Minghui Jiang, Ruixin Tan, Qintian Zhou, Zhidong Wang
{"title":"Comparative Efficacy of IL-17A Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis","authors":"Quan Zhou,&nbsp;Jingyue Ma,&nbsp;Xinzu Tong,&nbsp;Zhimin Wang,&nbsp;Huiping Wang,&nbsp;Powei Wu,&nbsp;Wangyang Zhao,&nbsp;Minghui Jiang,&nbsp;Ruixin Tan,&nbsp;Qintian Zhou,&nbsp;Zhidong Wang","doi":"10.1155/dth/9319875","DOIUrl":"https://doi.org/10.1155/dth/9319875","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Interleukin-17A (IL-17A) inhibitors demonstrate strong efficacy among biologic therapies for plaque psoriasis. However, comparative analyses within the IL-17A class, particularly studies including newer agents vunakizumab and xeligekimab, remain scarce.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To compare the efficacy and safety of four IL-17A inhibitors (secukinumab, ixekizumab, vunakizumab, and xeligekimab) for adult patients with moderate-to-severe plaque psoriasis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A systematic review and network meta-analysis of randomized controlled trials (RCTs) compared four IL-17A inhibitors with placebo. The protocol was registered with PROSPERO (CRD420251266904). Outcomes included PASI 75, 90, and 100 responses at Week 12. Treatments were ranked using the surface under the cumulative ranking curve (SUCRA). Safety outcomes were assessed descriptively.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Seventeen RCTs with 11,044 patients were included. All IL-17A inhibitors significantly outperformed placebo across efficacy endpoints at Week 12. Secukinumab 300 mg consistently ranked 1st for PASI 75 (SUCRA: 96.1%), PASI 90 (SUCRA: 93.8%), and PASI 100 (SUCRA: 95.3%). Vunakizumab 240 mg ranked 3rd for PASI 75 (SUCRA: 77.7%) but improved to 2nd place for PASI 90 (SUCRA: 80.0%) and PASI 100 (SUCRA: 81.9%), though with overlapping credible intervals relative to secukinumab 150 mg at these higher clearance endpoints. Secukinumab 150 mg ranked 2nd for PASI 75 (SUCRA: 82.1%) but 3rd place for PASI 90 (SUCRA: 73.0%) and 4th place for PASI 100 (SUCRA: 63.4%). Safety data were assessed descriptively only; no formal statistical comparison was performed. Observed adverse event rates varied across trials but could not be reliably compared due to differing observation windows and study designs.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Based on this network meta-analysis of Week 12 efficacy, secukinumab 300 mg achieved the highest SUCRA rankings across PASI 75, 90, and 100 endpoints, though credible intervals overlapped with other active treatments and all comparisons were indirect. These rankings are hypothesis-generating and should not be interpreted as evidence of definitive superiority; head-to-head trials are needed to confirm any between-agent differences. Vunakizumab 240 mg and secukinumab 150 mg also showed robust efficacy; however, overlapping credible intervals limit firm distinc","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9319875","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149259384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书